Medtronic Approaches Dividend King Status
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 21 2026
0mins
Source: NASDAQ.COM
- Dividend Growth Record: Medtronic has raised its dividend for 48 consecutive years, nearing Dividend King status, which reflects its strong business model and stable financial performance, likely attracting more long-term investors.
- Business Diversification: With a diversified portfolio across cardiovascular, neuroscience, and surgical sectors, Medtronic is set to maintain strong growth potential even after spinning off its diabetes business, ensuring competitiveness in the medical device industry.
- Innovation Drive: The introduction of the Hugo surgical robot exemplifies Medtronic's commitment to innovation in a fast-growing medical market, indicating that ongoing investments in technology will enhance future market share.
- Future Growth Expectations: Management projects a revenue growth of 5.5% for fiscal 2026, which is a solid target for a company with a market value of $120 billion, showcasing its potential to achieve growth during its transformation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 97.030
Low
102.00
Averages
111.76
High
120.00
Current: 97.030
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medtronic Continues Dividend Hike and Spins Off Diabetes Division
- Dividend Growth Record: Medtronic has increased its dividend for 48 consecutive years, with a recent yield of 2.9%, reflecting not only the company's strong operational capabilities but also indicating potential for continued dividend hikes, thereby boosting investor confidence.
- Spin-off of Diabetes Division: To focus on faster-growing businesses, Medtronic plans to spin off its diabetes division in early March, aiming for a valuation close to $8 billion, which will allow the company to concentrate resources on high-growth areas and enhance overall market competitiveness.
- Strong Financial Performance: Medtronic's recently reported third-quarter revenue grew by 8.7% year-over-year, and it secured FDA approval for its Hugo robotic surgery system, showcasing its innovation capabilities and laying a foundation for future growth, as the CEO noted plans to accelerate overall company performance.
- Attractive Valuation: With a forward P/E ratio of 16.3, slightly below its five-year average of 16.7, Medtronic presents an appealing investment opportunity, especially as it expands into robotic surgery, potentially offering long-term capital appreciation for investors.
See More
Medtronic's Growth Potential in Robotic Surgery
- Strong Revenue Growth: Medtronic recently reported an 8.7% year-over-year revenue increase in its third quarter, highlighting robust performance in the medical device sector, particularly following FDA approval for its Hugo robotic surgery system, which is expected to drive market expansion.
- Stable Dividend Returns: With a dividend yield of 2.9% and a history of increasing payouts for 48 consecutive years, Medtronic not only demonstrates solid financial health but also provides a reliable income stream for investors, enhancing its attractiveness.
- R&D Investment and Patent Advantage: Medtronic invests approximately $2.7 billion annually in research and development and holds over 41,000 active patents, showcasing its deep commitment to innovation and technology, which ensures its competitive edge in the medical device market.
- Strategic Restructuring and Market Focus: Medtronic plans to spin off its diabetes division in early March, aiming for a valuation close to $8 billion, allowing the company to concentrate on faster-growing business areas and further enhance its overall market value.
See More
Competitive Analysis of Surgical Robotics Market
- Market Leadership: Intuitive Surgical's da Vinci surgical systems reached 11,106 installations by the end of 2025, reflecting a 12% year-over-year increase, with surgeries performed rising 18%, indicating strong demand in the medical community, although only 25% of revenue comes from new robot sales, with the remainder from parts and services, creating a stable income stream.
- Competitive Opportunity: While Intuitive Surgical has a high P/E ratio of 64, Medtronic's more attractive valuation at 26, coupled with its rapidly developing surgical robot Hugo, which received FDA approval for U.S. use in late 2025, suggests significant growth potential ahead.
- Diversification Advantage: As one of the world's largest medical device companies, Medtronic's diversified product line supports its expansion into surgical robotics, positioning it to share in the rapidly growing market alongside Intuitive Surgical.
- Dividend Appeal: Medtronic offers a 2.9% dividend yield and is nearing Dividend King status, suggesting that as its Hugo system gains market share over the next decade, investors could see stock price appreciation, providing both income and growth opportunities.
See More
Intuitive Surgical's da Vinci Systems Drive Market Demand
- Growing Market Demand: By the end of 2025, Intuitive Surgical had installed 11,106 da Vinci surgical systems, reflecting a 12% year-over-year increase, indicating a significant rise in demand from the medical community and patients, thereby reinforcing its market leadership.
- Surgery Volume Increase: The number of surgeries performed using da Vinci systems rose by 18% year-over-year, showcasing the company's strong growth potential in surgical robotics, which may attract more investors looking for long-term value.
- Diversified Revenue Streams: While only 25% of the company's revenue comes from new robot sales, the ongoing income from parts and services provides a stable financial foundation, enhancing the sustainability and resilience of its business model.
- Competitive Landscape Shift: Medtronic's Hugo surgical robot, approved by the FDA at the end of 2025, may pose competitive pressure on Intuitive Surgical; although Hugo is not yet as advanced as da Vinci, its market potential could present significant growth opportunities for Medtronic.
See More
Medtronic Launches MiniMed Go System in Europe
- Product Launch: Medtronic has officially launched the MiniMed Go Smart MDI system in Europe, integrating the Simplera sensor to assist patients who require multiple daily injections in better managing their diabetes.
- Target Demographic: The system is approved for individuals aged 7 and older with insulin-requiring diabetes, and for children aged 2 to 6 under adult supervision, indicating a focus on diverse patient age groups.
- Market Rollout Plan: The MiniMed Go system will be gradually rolled out across Europe starting this month, which is expected to enhance Medtronic's competitiveness in the diabetes management market and meet the increasing patient demand.
- Stock Market Reaction: In pre-market trading on the NYSE, Medtronic shares fell by 0.18% to $96.60, reflecting a cautious market sentiment regarding the new product launch.
See More
Medtronic Launches MiniMed Go™ Smart MDI System in Europe
- Product Innovation: Medtronic has launched the MiniMed Go™ Smart MDI system in Europe, integrating the InPen™ smart insulin pen with the Simplera™ sensor to provide real-time data and personalized guidance, aimed at helping diabetes patients using multiple daily injections better manage their blood sugar levels.
- Market Impact: The rollout of this system across Europe is expected to significantly improve users' glycemic control, as research indicates that missing just two insulin doses per week can increase HbA1C by 0.4, raising the risk of complications.
- Enhanced User Experience: The MiniMed Go™ system offers real-time alerts and dose calculations via a smartphone app, with users responding to missed dose alerts achieving a Time in Range (TIR) of 67.2%, significantly higher than the cohort average of 55.7%, thereby improving treatment adherence.
- Clinical Support Tools: The new system provides healthcare professionals with CareLink Clinic MDI reports, simplifying the interpretation of user data and facilitating more effective patient discussions, thus enhancing the quality of care and patient satisfaction.
See More
Medtronic Continues Dividend Hike and Spins Off Diabetes Division
- Dividend Growth Record: Medtronic has increased its dividend for 48 consecutive years, with a recent yield of 2.9%, reflecting not only the company's strong operational capabilities but also indicating potential for continued dividend hikes, thereby boosting investor confidence.
- Spin-off of Diabetes Division: To focus on faster-growing businesses, Medtronic plans to spin off its diabetes division in early March, aiming for a valuation close to $8 billion, which will allow the company to concentrate resources on high-growth areas and enhance overall market competitiveness.
- Strong Financial Performance: Medtronic's recently reported third-quarter revenue grew by 8.7% year-over-year, and it secured FDA approval for its Hugo robotic surgery system, showcasing its innovation capabilities and laying a foundation for future growth, as the CEO noted plans to accelerate overall company performance.
- Attractive Valuation: With a forward P/E ratio of 16.3, slightly below its five-year average of 16.7, Medtronic presents an appealing investment opportunity, especially as it expands into robotic surgery, potentially offering long-term capital appreciation for investors.
See More
Medtronic's Growth Potential in Robotic Surgery
- Strong Revenue Growth: Medtronic recently reported an 8.7% year-over-year revenue increase in its third quarter, highlighting robust performance in the medical device sector, particularly following FDA approval for its Hugo robotic surgery system, which is expected to drive market expansion.
- Stable Dividend Returns: With a dividend yield of 2.9% and a history of increasing payouts for 48 consecutive years, Medtronic not only demonstrates solid financial health but also provides a reliable income stream for investors, enhancing its attractiveness.
- R&D Investment and Patent Advantage: Medtronic invests approximately $2.7 billion annually in research and development and holds over 41,000 active patents, showcasing its deep commitment to innovation and technology, which ensures its competitive edge in the medical device market.
- Strategic Restructuring and Market Focus: Medtronic plans to spin off its diabetes division in early March, aiming for a valuation close to $8 billion, allowing the company to concentrate on faster-growing business areas and further enhance its overall market value.
See More
Competitive Analysis of Surgical Robotics Market
- Market Leadership: Intuitive Surgical's da Vinci surgical systems reached 11,106 installations by the end of 2025, reflecting a 12% year-over-year increase, with surgeries performed rising 18%, indicating strong demand in the medical community, although only 25% of revenue comes from new robot sales, with the remainder from parts and services, creating a stable income stream.
- Competitive Opportunity: While Intuitive Surgical has a high P/E ratio of 64, Medtronic's more attractive valuation at 26, coupled with its rapidly developing surgical robot Hugo, which received FDA approval for U.S. use in late 2025, suggests significant growth potential ahead.
- Diversification Advantage: As one of the world's largest medical device companies, Medtronic's diversified product line supports its expansion into surgical robotics, positioning it to share in the rapidly growing market alongside Intuitive Surgical.
- Dividend Appeal: Medtronic offers a 2.9% dividend yield and is nearing Dividend King status, suggesting that as its Hugo system gains market share over the next decade, investors could see stock price appreciation, providing both income and growth opportunities.
See More
Intuitive Surgical's da Vinci Systems Drive Market Demand
- Growing Market Demand: By the end of 2025, Intuitive Surgical had installed 11,106 da Vinci surgical systems, reflecting a 12% year-over-year increase, indicating a significant rise in demand from the medical community and patients, thereby reinforcing its market leadership.
- Surgery Volume Increase: The number of surgeries performed using da Vinci systems rose by 18% year-over-year, showcasing the company's strong growth potential in surgical robotics, which may attract more investors looking for long-term value.
- Diversified Revenue Streams: While only 25% of the company's revenue comes from new robot sales, the ongoing income from parts and services provides a stable financial foundation, enhancing the sustainability and resilience of its business model.
- Competitive Landscape Shift: Medtronic's Hugo surgical robot, approved by the FDA at the end of 2025, may pose competitive pressure on Intuitive Surgical; although Hugo is not yet as advanced as da Vinci, its market potential could present significant growth opportunities for Medtronic.
See More
Medtronic Launches MiniMed Go System in Europe
- Product Launch: Medtronic has officially launched the MiniMed Go Smart MDI system in Europe, integrating the Simplera sensor to assist patients who require multiple daily injections in better managing their diabetes.
- Target Demographic: The system is approved for individuals aged 7 and older with insulin-requiring diabetes, and for children aged 2 to 6 under adult supervision, indicating a focus on diverse patient age groups.
- Market Rollout Plan: The MiniMed Go system will be gradually rolled out across Europe starting this month, which is expected to enhance Medtronic's competitiveness in the diabetes management market and meet the increasing patient demand.
- Stock Market Reaction: In pre-market trading on the NYSE, Medtronic shares fell by 0.18% to $96.60, reflecting a cautious market sentiment regarding the new product launch.
See More
Medtronic Launches MiniMed Go™ Smart MDI System in Europe
- Product Innovation: Medtronic has launched the MiniMed Go™ Smart MDI system in Europe, integrating the InPen™ smart insulin pen with the Simplera™ sensor to provide real-time data and personalized guidance, aimed at helping diabetes patients using multiple daily injections better manage their blood sugar levels.
- Market Impact: The rollout of this system across Europe is expected to significantly improve users' glycemic control, as research indicates that missing just two insulin doses per week can increase HbA1C by 0.4, raising the risk of complications.
- Enhanced User Experience: The MiniMed Go™ system offers real-time alerts and dose calculations via a smartphone app, with users responding to missed dose alerts achieving a Time in Range (TIR) of 67.2%, significantly higher than the cohort average of 55.7%, thereby improving treatment adherence.
- Clinical Support Tools: The new system provides healthcare professionals with CareLink Clinic MDI reports, simplifying the interpretation of user data and facilitating more effective patient discussions, thus enhancing the quality of care and patient satisfaction.
See More
